About GLP-1 Observer

GLP-1 Observer publishes focused, source-backed research notes on important developments in obesity and metabolic medicine. Each issue brings together the relevant trials, results, regulatory actions, and context so you can understand what changed, how the pieces fit together, and why it matters.

Who it’s for

Biotech operators, investors, clinicians, researchers, and others who follow the GLP-1 and obesity-drug landscape and want a clearer view of important developments without reconstructing the evidence themselves.

What to expect

• Focused synthesis of consequential developments

• Trial, readout, and pipeline comparisons

• Program maps and reusable evidence frames

• Direct links to supporting sources

Issues are published when the available evidence supports a useful synthesis, not to fill a weekly schedule.

For weekly changes

The public GLP-1 Weekly Updates page tracks recurring trial changes, results, regulatory events, registrations, and industry news.

Help shape coverage

Reply to any issue with a development or question that you think deserves a deeper, source-backed synthesis. Reader questions help shape what gets covered.

Who’s behind it

Michael Parker, MD / computer scientist. Former Harvard Medical School faculty; founded and led HMX, an online learning product used widely in biotech and pharma. Now building source-backed tools that help the biotech community follow fast-moving developments, starting with GLP-1 and obesity medicine.

LinkedIn · Contact: glp1observer@substack.com (or reply to any email)